Pipeline
First-in-class oncology programmes
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
MAPK Pathway
- 18% 18%
Synthetic Lethality
In Partnership with:
- 18% 18%
First-in-class Gram-negative antibacterial programmes
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
OPT-200 LPS Inhibitor
- 20% 20%
OPT-500 Isoprenoid Biosynthesis
In Partnership with:
- 18% 18%
OPT-600 Isoprenoid Biosynthesis
In Partnership with:
- 18% 18%
Whole cell dynamic computational model of E. coli
Most advanced model of its kind currently covering >3000 genes.
We have used systems biology and Machine learning to build a detailed dynamic model of E.coli.
The model is utilised to discover new biology and identify viable drug targets.